SCYNEXIS receives payment as part of pharmaceutical discovery program with Merial

Merial Limited and SCYNEXIS, Inc. announced today that SCYNEXIS has earned a payment for meeting certain milestones in its multi-year research collaboration with Merial Limited, which began in 2005. SCYNEXIS, a premier drug discovery and development company, focuses considerable medicinal chemistry, advanced biological screening, bioanalytical and ADMET efforts towards Merial’s animal health discovery efforts.

“Merial is excited about the continued success of our pharmaceutical discovery program. Together with Scynexis we have reached another milestone in our program that focuses on designing novel compounds that specifically address animal health needs,” said Dr. Peter Hanson, Head of Pharmaceutical R&D, of Merial.

“SCYNEXIS is pleased to have reached another important milestone in the discovery of animal health solutions with our valued partner Merial,” said SCYNEXIS President and CEO Dr. Yves Ribeill. “The achievement of this milestone, which is the third associated with the agreement, demonstrates SCYNEXIS’ ability to bring innovation to the animal health pharmaceutical area.”